Differential vulnerability to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum
MT Herrero, EC Hirsch, F Javoy-Agid, JA Obeso… - Brain research, 1993 - Elsevier
MT Herrero, EC Hirsch, F Javoy-Agid, JA Obeso, Y Agid
Brain research, 1993•ElsevierParkinson's disease is characterized by a loss of dopaminergic neurons in the substantia
nigra and, in the most severe cases, by degeneration of mesopontine cholinergic neurons.
In a monkey model of Parkinson's disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine we report that, despite a severe loss of dopaminergic neurons, in the
mesopontine tegmentum cholinergic neurons are preserved in the same region. This
suggests that the loss of mesopontine cholinergic neurons in parkinsonian patients may …
nigra and, in the most severe cases, by degeneration of mesopontine cholinergic neurons.
In a monkey model of Parkinson's disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine we report that, despite a severe loss of dopaminergic neurons, in the
mesopontine tegmentum cholinergic neurons are preserved in the same region. This
suggests that the loss of mesopontine cholinergic neurons in parkinsonian patients may …
Abstract
Parkinson's disease is characterized by a loss of dopaminergic neurons in the substantia nigra and, in the most severe cases, by degeneration of mesopontine cholinergic neurons. In a monkey model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine we report that, despite a severe loss of dopaminergic neurons, in the mesopontine tegmentum cholinergic neurons are preserved in the same region. This suggests that the loss of mesopontine cholinergic neurons in parkinsonian patients may represent an end-stage degenerative process, the cause of which may be independent of the mechanism of dopaminergic cell death.
Elsevier
